Shots:

• The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg- qd) as monothx in adults patients previously treated- LA or metastatic cholangiocarcinoma with documented FGF/FGFR status divided into 3 cohorts: Cohort A (N=107- FGFR2 fusions or rearrangements)- Cohort B (N=20- other FGF/FGFR genetic alterations) or Cohort C (N=18- no FGF/FGFR genetic alterations)  
• P-II FIGHT-202 results: ORR 36%- mDOR 7.5 mos.- DCR 82%- mPFS 6.9mos.- Preliminary OS 21.1mos.- well-tolerated results; Presented at ESMO 2019  
• Pemigatinib is a selective oral inhibitor of FGFR isoforms 1- 2 and 3- also received FDA’s Breakthrough Therapy Designation for the treatment of previously treated- advanced/metastatic or unresectable FGFR2 translocated cholangiocarcinoma with its planned NDA submission to the US FDA before end of H2’19

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance